/

/

EGFR変異型NSCLC患者由来オルガノイドにおける標的療法に対する感受性のプロファイリング

JoVE Journal
Krebsforschung

This content is Free Access.

JoVE Journal Krebsforschung

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Please note that all translations are automatically generated. Click here for the English version.

EGFR変異型NSCLC患者由来オルガノイドにおける標的療法に対する感受性のプロファイリング

3,451 Views

•

08:52 min

•

November 22, 2021

DOI:

10.3791/63039-v

DOI:

10.3791/63039-v

•

08:52 min

November 22, 2021

•

2 Views

Dora Barbosa Rabago^2,3, Collin M. Blakely², Franziska Haderk^2,3, Trever G. Bivona^2,3

¹Department of Medicine,University of California, San Francisco, ²Helen Diller Family Comprehensive Cancer Center,University of California, San Francisco, ³Department of Cellular and Molecular Pharmacology,University of California, San Francisco

Tags

Organoids EGFR-mutant NSCLC Targeted Therapies Matrigel Cell Culture Dissociation Trypsinization Centrifugation Cell Counting Cell Suspension 96-well Plate

Read Article